hydrocotarnine

Known as: 1,3-dioxolo(4,5-g)isoquinoline, 5,6,7,8-tetrahydro-4-methoxy-6-methyl- 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Tetrahydroisoquinolines

Narrower (2)

hydrocotarnine hydrobromidehydrocotarnine hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Src-family kinase-Cbl axis negatively regulates NLRP3 inflammasome activation
Activation of the NLRP3 inflammasome is crucial for immune defense, but improper and excessive activation causes inflammatory… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Continuous subcutaneous infusion of compound oxycodone for the relief of dyspnea in patients with terminally ill cancer: a retrospective study.
Pain and dyspnea are the most prevalent and distressing symptoms in patients with terminally ill cancer. Evidences have… Expand
Is this relevant?
2012
2012
[Retrospective study on intravenous compound injection of cancer pain patients with oxycodone and hydrocotarnine preparation in comparison with subcutaneous administration].
In Japan, although oral oxycodone is widely used for cancer pain treatment, there is no injection preparation of oxycodone used… Expand
Is this relevant?
2009
2009
Effect of hydrocotarnine on cytochrome P450 and P-glycoprotein.
The injectable form of oxycodone contains hydrocotarnine that is supposed to potentiate the analgesic effect of oxycodone with… Expand
Is this relevant?
2009
2009
[Efficacy and safety of continuous subcutaneous injection of the compound oxycodone in cancer pain management: the first 4-year audit].
The compound oxycodone injection, but not pure oxycodone, has been available since the 1920's in Japan. The compound, containing… Expand
Is this relevant?
2007
2007
Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain.
Compound injections of oxycodone and hydrocotarnine are currently used as one of the treatment options for some cases with cancer… Expand
  • table 2
  • table 1
  • figure 1
  • figure 2
  • figure 4
Is this relevant?
Review
2007
Review
2007
[Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain].
The demand for oxycodone increases in the treatment of patients with cancer pain, but there is no injection formulation… Expand
Is this relevant?
2006
2006
Comparison of the various opiate alkaloid contaminants and their metabolites found in illicit heroin with 6-monoacetyl morphine as indicators of heroin ingestion.
In this study the use of the various opiate alkaloid contaminants as potential markers for illicit heroin ingestion were… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table II
Is this relevant?
2005
2005
Determination of oxycodone and hydrocotarnine in cancer patient serum by high-performance liquid chromatography with electrochemical detection.
We developed an HPLC procedure using electrochemical detection for the quantitation of oxycodone and hydrocotarnine in cancer… Expand
  • figure 1
  • table 2
  • figure 2
Is this relevant?
1979
1979
[Biotransformation and Stability of Hydrocotarnine and Diazocarbonylhydrocotarnine and -hydrohydrastinine derivatives (author's transl)].
After oral application of the weakly basic (pKs = 6.18-6.26) and relatively stable (1 at pH = 7.4; t1/2(35 degrees C) = 6.9 h… Expand
Is this relevant?